Lan Bao

Dr. Lan Bao

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2025 in Nanomaterials
Verified
Journal Article
Open access
PDF file
MGMingming Gao
Mingming Gao
MZMinghao Zhao
Minghao Zhao
QYQianqian Yang
Qianqian Yang
LBLan Bao
Lan Bao
LCLiwei Chen
Liwei Chen
JFJing Feng
Jing Feng
Nanomaterials with large specific surface area (SSA) have emerged as pivotal platforms for energy storage and environmental remediation, primarily due to their enhanced active site exposure, improved mass transport capabilities, and superior interfacial reactivity. Among them, polymeric carbon nitride (g-C3N4) has garnered significant attention in energy and environmental applications owing to its visible-light-responsive bandgap (~2.7 eV), exceptional thermal/chemical stability, and earth-abundant composition. However, the practical performance of g-C3N4 is fundamentally constrained by intrinsic limitations, including its inherently low SSA (<20 m2/g via conventional thermal polymerization), rapid recombination of photogenerated carriers, and inefficient charge transfer kinetics. Notably, the theoretical SSA of g-C3N4 reaches 2500 m2/g, yet achieving this value remains challenging due to strong interlayer van der Waals interactions and structural collapse during synthesis. Recent advances demonstrate that state-of-the-art strategies can elevate its SSA to 50–200 m2/g. To break this surface area barrier, advanced strategies achieve SSA enhancement through three primary pathways: pre-treatment (molecular and supramolecular precursor design), in process (templating and controlled polycondensation), and post-processing (chemical exfoliation and defect engineering). This review systematically examines controllable synthesis methodologies for high-SSA g-C3N4, analyzing how SSA amplification intrinsically modulates band structures, extends carrier lifetimes, and boosts catalytic efficiencies. Future research should prioritize synergistic multi-stage engineering to approach the theoretical SSA limit (2500 m2/g) while preserving robust optoelectronic properties.

4 September 2026 in Frontiers of Materials Science
Verified
Journal Article
Closed access
PDF file
YLYan Liu
Yan Liu
FLFang Li
Fang Li
JPJingwen Peng
Jingwen Peng
LBLan Bao
Lan Bao

8 October 2026 in Biology
Verified
Journal Article
Open access
PDF file
HLHao Li
Hao Li
JHJiewen Hou
Jiewen Hou
CHCongzhen He
Congzhen He
CLChangxing Liu
Changxing Liu
BRBowen Ran
Bowen Ran
HHHui-Zi Huang
Hui-Zi Huang
Pancreatic diseases, particularly pancreatic ductal adenocarcinoma (PDAC), remain among the most challenging disorders to diagnose and treat owing to a series of interconnected biological barriers, including dense stromal desmoplasia, profound immunosuppression, hypoxia, therapeutic resistance, and the lack of effective early-detection strategies. Overcoming these barriers requires multifunctional platforms capable of integrating diagnosis, microenvironment regulation, and precision therapy within a single system. Metal–organic frameworks (MOFs), a class of highly tunable porous crystalline materials, have emerged as uniquely suited candidates for this purpose because of their programmable composition, structural versatility, catalytic activity, and capacity for multifunctional integration. Notably, MOFs have evolved from passive drug carriers into active regulators of disease-associated biological processes, enabling enhanced drug delivery, extracellular matrix remodeling, ferroptosis- and cuproptosis-based precision therapy, energy-triggered reactive oxygen species generation, immune microenvironment reprogramming, and imaging-guided theranostics. Beyond pancreatic cancer, emerging evidence further supports their potential applications in pancreatitis management and interventional therapeutic enhancement. In this review, we systematically summarize recent advances in the rational engineering of MOFs for pancreatic diseases, focusing on how material design strategies are leveraged to overcome key pathological barriers and improve therapeutic outcomes. We further discuss current challenges associated with biosafety, biodegradation, large-scale manufacturing, and clinical translation, while highlighting future opportunities for the development of next-generation MOF-based precision nanomedicines. By integrating advances across materials science, nanomedicine, and pancreatic disease biology, this review provides a comprehensive framework for the design and translational development of MOF-enabled diagnostic and therapeutic platforms.

21 September 2026 in ChemistrySelect
Verified
Journal Article
Open access
PDF file
LBLan Bao
Lan Bao
XSXinzhe Song
Xinzhe Song
MGMingming Gao
Mingming Gao
SHSuqin Han
Suqin Han
LCLiwei Chen
Liwei Chen
SYShengbiao Yang
Shengbiao Yang
Fibroblast activation protein (FAP) is frequently overexpressed on cancer‐associated fibroblasts across a broad range of epithelial malignancies while showing limited expression in most normal adult tissues, making it an attractive target for cancer theranostics. This review proposes a conceptual clinical selection framework to guide the potential application of FAP‐targeted radiopharmaceuticals. Three molecular platforms, including small‐molecule FAP inhibitors (FAPIs), antibody‐based/nanobody‐based agents, and peptide‐based ligands, were systematically compared according to pharmacokinetics, tumor retention, and available clinical evidence. Small‐molecule FAPIs enable high‐contrast PET imaging, with reported staging changes in approximately one‐third of patients, but their therapeutic application is limited by short tumor retention and insufficient absorbed dose. Antibody‐based platforms provide prolonged circulation that may support α‐emitter therapy but require careful consideration of dosimetry and hematologic toxicity, whereas peptide‐based agents such as FAP‐2286 offer an intermediate pharmacokinetic profile with favorable tolerability. Three priority areas were identified: overcoming FAP heterogeneity (∼18% eligibility), standardizing dosimetry, and expanding α‐emitter accessibility. This review proposes a triage framework for platform selection and highlights rational combinations with immune checkpoint inhibitors as a promising strategy for improving the therapeutic potential of FAP‐targeted radioligand therapy. FAP‐targeted radiopharmaceuticals represent an emerging theranostic strategy with promising diagnostic applications and evolving therapeutic potential.

27 October 2026 in Asian Journal of Organic Chemistry
Verified
Journal Article
Closed access
SYShengbiao Yang
Shengbiao Yang
ALAotian Li
Aotian Li
JSJian Sheng
Jian Sheng
LBLan Bao
Lan Bao
MSMiao Sun
Miao Sun
CYChunhao Yuan
Chunhao Yuan